| Literature DB >> 36079837 |
Lourdes Herrera-Quintana1, Héctor Vázquez-Lorente1, Jorge Molina-López2, Yenifer Gamarra-Morales1, Javier Ignacio Martín-López3, Elena Planells1.
Abstract
Critically ill patients are exposed to different stressors which may generate Systemic Inflammatory Response Syndrome (SIRS). This situation hinders the assessment of micronutrients status, such as vitamin D or Zinc (Zn), potentially affecting patients' treatment and recovery. The aim of the present study was to assess the evolution of circulating 25-Hydroxyvitamin D (25-OH-D) levels after seven days of Intensive Care Unit (ICU) stay and the influence on changes in plasma and erythrocyte Zn levels, as well as other parameters related to phosphorus-calcium metabolism. A prospective analytical study was conducted on 65 critically ill patients (42% women) aged 31-77 years with SIRS. Total 25-OH-D levels were measured in plasma samples by liquid chromatography-tandem mass spectrometry, and Zn content was analyzed by flame atomic absorption spectrometry. Both 25-OH-D and 25-OH-D3 levels were directly associated with erythrocyte Zn concentration at follow-up (p = 0.046 and p = 0.011, respectively). A relationship between erythrocyte and plasma Zn was also found at this follow-up point. No such clear associations were found when considering 25-OH-D2. Different disturbances in levels of phosphorus-calcium metabolism parameters were found, suggesting a relationship between the changes of 25-OH-D3 levels and parathormone (p = 0.019) and phosphorus (p = 0.005). The findings of the present study suggest an interaction between vitamin D and Zn, in which the correct status of these micronutrients could be a potentially modifiable factor and a beneficial approach in the recovery of critically ill patients.Entities:
Keywords: Intensive Care Unit; Systemic Inflammatory Response Syndrome; Zinc; critically ill patient; vitamin D
Mesh:
Substances:
Year: 2022 PMID: 36079837 PMCID: PMC9494352 DOI: 10.3390/nu14173580
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Comparative analysis of the studied parameters at baseline and follow-up.
| Parameters | Reference | Baseline | Follow-Up | Δ Change | |||
|---|---|---|---|---|---|---|---|
| Age (years) | - | 60.1 (11.5) | - | - | 0.747 | - | - |
| BMI (kg/m2) | - | 26.7 (4.77) | - | - | 0.320 |
| - |
| Patient 7-day mortality (n/N, %) | - | 25/65 (38.5) | - | - | 0.474 | 0.070 | - |
| APACHE-II score | - | 17.2 (4.94) | - | - | 0.390 | 0.895 | - |
| SOFA score | - | 9.04 (3.39) | 5.12 (3.50) | −43.4 | 0.230 | 0.264 |
|
| Total Proteins (g/dL) | 6.60–8.30 | 5.27 (0.91) | 5.53 (0.76) | +4.93 | 0.138 | 0.658 | 0.115 |
| Albumin (g/dL) | 3.50–5.20 | 2.85 (0.58) | 2.63 (0.67) | −7.72 | 0.647 | 0.649 | 0.139 |
| Prealbumin (mg/dL) | 16.0–42.0 | 12.5 (4.65) | 16.3 (9.80) | +30.3 | 0.370 | 0.828 | 0.143 |
| Ferritin (ng/dL) | 20.0–275.0 | 401.6 (377.4) | 543.7 (482.9) | +35.4 | 0.861 | 0.493 |
|
| Transferrin (mg/dL) | 200.0–360.0 | 153.4 (63.1) | 146.9 (50.8) | −4.27 | 0.825 | 0.868 | 0.514 |
| Triglycerides (mg/dL) | 50.0–200.0 | 196.9 (144.3) | 197.8 (102.1) | +0.46 | 0.275 | 0.366 | 0.972 |
| Total Cholesterol (mg/dL) | 140.0–200.0 | 108.5 (38.2) | 134.8 (43.7) | +24.2 | 0.875 | 0.521 |
|
| CRP (mg/L) | 0.00–5.00 | 19.8 (11.8) | 10.7 (8.63) | −46.2 | 0.292 | 0.164 |
|
| GOT (U/L) | <37.0 | 104.0 (164.0) | 36.2 (23.2) | −65.2 | 0.290 | 0.260 |
|
| GPT (U/L) | <41.0 | 54.9 (78.8) | 28.5 (26.0) | −48.0 | 0.801 | 0.349 | 0.082 |
| GGT (U/L) | 11.0–50.0 | 56.6 (60.9) | 141.3 (98.4) | +149.7 | 0.932 | 0.473 |
|
| ALP (U/L) | 40.0–130.0 | 101.5 (76.3) | 126.1 (68.8) | +24.3 | 0.085 | 0.133 | 0.062 |
| Osteocalcin (ng/mL) | 15.0–46.0 | 2.97 (1.95) | 5.53 (3.98) | +86.2 | 0.385 | 0.163 |
|
| PTH (pg/mL) | 20.0–70.0 | 248.5 (151.0) | 133.5 (97.9) | −46.3 |
| 0.775 |
|
| Ca (mg/dL) | 8.80–10.6 | 7.53 (0.86) | 8.06 (0.71) | +7.04 | 0.930 | 0.812 |
|
| P (mg/dL) | 2.30–4.50 | 3.91 (1.87) | 3.65 (1.47) | −6.65 | 0.152 | 0.676 | 0.452 |
| Mg (mg/dL) | 1.60–2.60 | 2.14 (0.52) | 2.31 (0.46) | +7.94 | 0.564 | 0.320 | 0.213 |
Data are expressed as mean (standard deviation). Abbreviations: ALP = Alkaline Phosphatase; APACHE-II = Acute Physiology and Chronic Health Evaluation II; BMI = Body Mass Index; Ca = Calcium; CRP = C-Reactive Protein; GGT = Gamma-Glutamyl Transferase; GOT = Glutamic Oxaloacetic Transaminase; GPT = Glutamic Pyruvic Transaminase; Mg = Magnesium; P = Phosphorus; PTH = Parathormone; SOFA = Sequential Organ Failure Assessment. Δ Change (%) = percentage change from baseline to follow-up. Qualitative variables were compared inter-groups using Chi-square test. Quantitative variables were compared inter-groups using the unpaired Student t-test for parametric samples, and intra-groups using the paired Student t-test for parametric samples. Median age (62 years old) was used as cutoff to analyze the differences between lower and higher ages. Significant p-Values are shown in boldface. Statistical significance was considered for p < 0.05.
Comparative analysis of the studied parameters at baseline and follow-up.
| Parameters | Reference | Baseline | Follow-Up | Δ Change | |
|---|---|---|---|---|---|
| 25–OH–D (ng/mL) | 30.0–100.0 | 6.76 (2.96) | 6.51 (3.28) | −3.11 | 0.506 |
| 25–OH–D3 (ng/mL) | – | 3.90 (2.23) | 3.59 (2.10) | −7.18 |
|
| 25–OH–D2 (ng/mL) | – | 2.87 (1.60) | 2.93 (2.05) | +2.09 | 0.875 |
| Plasma Zn (mg/L) | 0.65–1.11 | 0.71 (0.51) | 0.74 (0.56) | +4.23 | 0.748 |
| Erythrocyte Zn (mg/L) | – | 6.22 (2.81) | 6.42 (2.90) | +3.12 | 0.708 |
|
|
| ||||
| 25–OH–D deficiency | <20 ng/mL | 65/65 (100) | 40/40 (100) | 0 | - |
| Hypozincemia (plasma Zn) | <0.7 mg/L | 28/65 (43) | 13/40 (32.5) | −24.4 |
|
Data are expressed as mean (Standard Deviation). Abbreviations: Zn = Zinc; 25–OH–D = 25-Hydroxyvitamin D; 25–OH–D3 = 25-Hydroxyvitamin D3; 25–OH–D2 = 25-Hydroxyvitamin D2. Δ Change (%) = percentage change from baseline to follow-up. n = number of participants who presented deficient biochemical values. For the comparative analysis of quantitative variables, the paired Student t-test for parametric samples was used. Qualitative variables were compared inter-groups using Chi-square test. Significant p-Values are shown in boldface. Statistical significance was considered for p < 0.05.
Figure 1Associations between vitamin D and Zn levels at baseline and follow-up. (A) 25–OH–D levels with erythrocyte Zn at baseline. (B) 25–OH–D levels with erythrocyte Zn at follow-up. (C) 25–OH–D3 levels with erythrocyte Zn at baseline. (D) 25–OH–D3 levels with erythrocyte Zn at follow-up. (E) 25–OH–D2 levels with erythrocyte Zn at baseline. (F) 25–OH–D2 levels with erythrocyte Zn at follow-up. (G) Erythrocyte Zn with plasma Zn at baseline. (H) Erythrocyte Zn with plasma Zn at follow-up. β (standardized regression coefficient), R2, and p are provided for simple and multiple linear regression analyses. Model 0; unadjusted, Model 1; adjusted for age, Model 2; adjusted for age and sex. Abbreviations: Zn = Zinc; 25–OH–D = 25–Hydroxyvitamin D; 25–OH–D3 = 25–Hydroxyvitamin D3. Significant p-Values are shown in boldface. Statistical significance was considered for p < 0.05.
Associations between changes in vitamin D and changes in phosphorus–calcium metabolism parameters after 7 days of ICU stay.
| Characteristics | Δ 25–OH–D | Δ 25–OH–D3 | Δ 25–OH–D2 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| ß | R2 | ß | R2 | ß | R2 | ||||
|
| 0.091 | 0.008 | 0.672 | −0.260 | 0.067 | 0.221 | 0.202 | 0.041 | 0.343 |
|
| 0.211 | 0.044 | 0.334 | 0.484 | 0.234 |
| −0.015 | 0.001 | 0.945 |
|
| −0.256 | 0.065 | 0.218 | 0.044 | 0.002 | 0.833 | −0.256 | 0.065 | 0.218 |
|
| 0.329 | 0.108 | 0.109 | 0.539 | 0.291 |
| 0.115 | 0.013 | 0.585 |
|
| −0.388 | 0.150 | 0.061 | 0.069 | 0.005 | 0.748 | −0.402 | 0.161 | 0.052 |
ß = standardized regression coefficient. R2 and p are from simple regression analysis. Abbreviations: Mg = Magnesium; P = Phosphorus; PTH = Parathormone; 25–OH–D = 25–Hydroxyvitamin D; 25–OH–D3 = 25–Hydroxyvitamin D3; 25–OH–D2 = 25–Hydroxyvitamin D2. Bold numbers indicate a statistically significant association. Significance was set at p-Value < 0.05.